scholarly journals Tis7 deletion reduces survival and induces intestinal anastomotic inflammation and obstruction in high-fat diet-fed mice with short bowel syndrome

2014 ◽  
Vol 307 (6) ◽  
pp. G642-G654 ◽  
Author(s):  
Amy M. Garcia ◽  
Derek Wakeman ◽  
Jianyun Lu ◽  
Christopher Rowley ◽  
Taylor Geisman ◽  
...  

Effective therapies are limited for patients with parenteral nutrition-dependent short bowel syndrome. We previously showed that intestinal expression of the transcriptional coregulator tetradecanoyl phorbol acetate-induced sequence 7 ( tis7) is markedly increased during the adaptive response following massive small bowel resection and tis7 plays a role in normal gut lipid metabolism. Here, we further explore the functional implications of tis7 deletion in intestinal lipid metabolism and the adaptive response following small bowel resection. Intestinal tis7 transgenic ( tis7tg), tis7−/−, and wild-type (WT) littermates were subjected to 50% small bowel resection. Mice were fed a control or a high-saturated-fat (42% energy) diet for 21 days. Survival, body weight recovery, lipid absorption, mucosal lipid analysis, and the morphometric adaptive response were analyzed. Quantitative real-time PCR was performed to identify tis7 downstream gene targets. Postresection survival was markedly reduced in high-fat, but not control, diet-fed tis7−/− mice. Decreased survival was associated with anastomotic inflammation and intestinal obstruction postresection. High-fat, but not control, diet-fed tis7−/− mice had increased intestinal IL-6 expression. Intestinal lipid trafficking was altered in tis7−/− compared with WT mice postresection. In contrast, high-fat diet-fed tis7tg mice had improved survival postresection compared with WT littermates. High-fat diet feeding in the setting of tis7 deletion resulted in postresection anastomotic inflammation and small bowel obstruction. Tolerance of a calorie-rich, high-fat diet postresection may require tis7 and its target genes. The presence of luminal fat in the setting of tis7 deletion promotes an intestinal inflammatory response postresection.

2013 ◽  
Vol 18 (2) ◽  
pp. 286-294 ◽  
Author(s):  
Pamela M. Choi ◽  
Raphael C. Sun ◽  
Jun Guo ◽  
Christopher R. Erwin ◽  
Brad W. Warner

2014 ◽  
Vol 307 (4) ◽  
pp. G410-G419 ◽  
Author(s):  
Ryo Sueyoshi ◽  
Kathleen M. Woods Ignatoski ◽  
Manabu Okawada ◽  
Bolette Hartmann ◽  
Jens Holst ◽  
...  

Glucagon-like peptide-2 (GLP-2) has been shown to be effective in patients with short bowel syndrome (SBS), but it is rapidly inactivated by dipeptidyl peptidase IV (DPP4). We used an orally active DPP4 inhibitor (DPP4-I), MK-0626, to determine the efficacy of this approach to promote adaptation after SBS, determined optimal dosing, and identified further functional actions in a mouse model of SBS. Ten-week-old mice underwent a 50% proximal small bowel resection. Dose optimization was determined over a 3-day post-small bowel resection period. The established optimal dose was given for 7, 30, and 90 days and for 7 days followed by a 23-day washout period. Adaptive response was assessed by morphology, intestinal epithelial cell (IEC) proliferation (proliferating cell nuclear antigen), epithelial barrier function (transepithelial resistance), RT-PCR for intestinal transport proteins and GLP-2 receptor, IGF type 1 receptor, and GLP-2 plasma levels. Glucose-stimulated sodium transport was assessed for intestinal absorptive function. Seven days of DPP4-I treatment facilitated an increase in GLP-2 receptor levels, intestinal growth, and IEC proliferation. Treatment led to differential effects over time, with greater absorptive function at early time points and enhanced proliferation at later time points. Interestingly, adaptation continued in the group treated for 7 days followed by a 23-day washout. DPP4-I enhanced IEC proliferative action up to 90 days postresection, but this action seemed to peak by 30 days, as did GLP-2 plasma levels. Thus DPP4-I treatment may prove to be a viable option for accelerating intestinal adaptation with SBS.


2012 ◽  
Vol 142 (5) ◽  
pp. S-91
Author(s):  
Amy M. Garcia ◽  
Derek Wakeman ◽  
Christopher W. Rowley ◽  
Jianyun Lu ◽  
Shashi Bala ◽  
...  

2011 ◽  
Vol 135 (2) ◽  
pp. 195-202 ◽  
Author(s):  
Prue M. Pereira-Fantini ◽  
Sarah L. Thomas ◽  
Guineva Wilson ◽  
Russell G. Taylor ◽  
Magdy Sourial ◽  
...  

2000 ◽  
Vol 118 (6) ◽  
pp. 169-172 ◽  
Author(s):  
Simone Chaves Miranda ◽  
Michelle Lizzy Bandeira Ribeiro ◽  
Eduardo Ferriolli ◽  
Júlio Sérgio Marchini

CONTEXT: Magnesium support to small bowel resection patients. OBJECTIVE: Incidence and treatment of hypomagnesemia in patients with extensive small bowel resection. DESIGN: Retrospective study. SETTING: Metabolic Unit of the University Hospital Medical School of Ribeirão Preto, University of São Paulo, Brazil. PATIENTS: Fifteen patients with extensive small bowel resection who developed short bowel syndrome. MAIN MEASUREMENTS: Serum magnesium control of patients with bowel resection. Replacement of magnesium when low values were found. RESULTS: Initial serum magnesium values were obtained 21 to 180 days after surgery. Hypomagnesemia [serum magnesium below 1.5 mEq/l (SD 0.43)] was detected in 40% of the patients [1,19 mEq/l (SD 0.22)]. During the follow-up period, 66% of the patients presented at least two values below reference (1.50 mEq/l). 40% increased their serum values after magnesium therapy. CONCLUSION: Metabolic control of serum magnesium should be followed up after extensive small bowel resection. Hypomagnesemia may be found and should be controlled.


2013 ◽  
Vol 144 (5) ◽  
pp. S-1065-S-1066 ◽  
Author(s):  
Pamela M. Choi ◽  
Raphael C. Sun ◽  
Jun Guo ◽  
Christopher R. Erwin ◽  
Brad Warner

Sign in / Sign up

Export Citation Format

Share Document